Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

19 mars 2019 10h00 HE | Source: Zoom Video Communications

Zoom and HP Collaborate to Create Modern Workspaces for Today’s Workforce

SAN JOSE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. today announced a partnership with HP Inc. to meet the collaboration needs of today’s teams for video-first...
29 nov. 2018 06h00 HE | Source: Invivoscribe, Inc.

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
28 nov. 2018 04h53 HE | Source: Invivoscribe, Inc.

Invivoscribe reicht Anträge für das LeukoStrat CDx FLT3-Mutations-Assay sowohl in den USA als auch in Japan ein, um die Anträge von Daiichi Sankyo für Quizartinib zu unterstützen

SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Invivoscribe freut sich bekanntgeben zu können, dass das Unternehmen zur Unterstützung einer laufenden Partnerschaft mit Daiichi Sankyo für den...
27 nov. 2018 06h00 HE | Source: Invivoscribe, Inc.

Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib

SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
19 nov. 2018 08h00 HE | Source: Invivoscribe, Inc.

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
28 sept. 2018 01h42 HE | Source: Invivoscribe, Inc.

Invivoscribe® erhält in Japan die Zulassung für seinen LeukoStrat® CDx FLT3-Mutations-Assay zur Beurteilung von Patienten mit akuter myeloischer Leukämie (AML), die mit Xospata® (Gilteritinib-Fumarat) behandelt werden können

SAN DIEGO, Kalifornien, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., ein weltweit tätiges Unternehmen, das Biomarker- und Klonalitätsstest für die Bereiche Onkologie und personalisierte...
27 sept. 2018 06h00 HE | Source: Invivoscribe, Inc.

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine®...
24 mai 2018 09h00 HE | Source: Nuxeo Corporation

Nuxeo Named One of Inc. Magazine’s 2018 Best Workplaces

NEW YORK, May 24, 2018 (GLOBE NEWSWIRE) -- Nuxeo, the leading cloud-native Content Services Platform, today announced the company’s selection as one of Inc. Magazine’s Best Workplaces for 2018, the...
16 mai 2018 04h28 HE | Source: Invivoscribe, Inc.

Invivoscribe lança o exame LymphoTrack Dx TRB como kit IVD com certificação CE, completando o conjunto de clonalidade NGS para a plataforma MiSeq

SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- A Invivoscribe Technologies Inc., uma empresa global com décadas de experiência no fornecimento de soluções de testes de clonalidade e biomarcadores para...
16 mai 2018 04h28 HE | Source: Invivoscribe, Inc.

Invivoscribe发布获得CE认证的体外诊断套盒LymphoTrack Dx TRB检定盒，为MiSeq平台的下一代测序克隆套件再添新成员

美国圣地亚哥, May 16, 2018 (GLOBE NEWSWIRE) -- 在为肿瘤学和个性化分子医学领域提供克隆和生物标记测试解决方案上拥有数十年经验的全球性企业Invivoscribe Technologies Inc.今日发布了用于Illumina® MiSeq®平台的LymphoTrack® Dx TRB...

Page précédente

Page suivante